AZP-531
Phase 1- Indications
- Type 2 diabetes, Prader Willi syndrome, Ischemia-related cardiovascular conditions
Company intelligence / Profile preview
Alizé Pharma
Ecully/Lyon, Auvergne-Rhône-Alpes, Franceorpha.net ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Alizé Pharma was a French biopharmaceutical group focused on developing innovative peptides and proteins targeting rare endocrine/metabolic diseases and certain cancers. Its lead program AZP‑531 showed encouraging efficacy/tolerability in a Phase II trial for Prader-Willi syndrome before being acquired by Millendo Therapeutics. Another key program, ASPAREC®, targeted acute lymphoblastic leukemia with a novel PEGylated recombinant L-asparaginase partnered with Jazz Pharmaceuticals. The third entity, Alizé Pharma 3—now Amolyt Pharma—continues to develop first-in-class peptides for rare endocrine/metabolic disorders such as hypoparathyroidism and severe insulin resistance.[5][4]
- Therapeutic areas
- CardiovascularMetabolic DisordersEndocrinologyOncologyRare Diseases
- Modalities
- Peptides[1][2][3]Proteins[1][2]Recombinant enzymes (e.g., PEGylated L-asparaginase)[1]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Jazz Pharmaceuticals – partnership/acquisition related to ASPAREC® [1].Millendo Therapeutics – acquisition partner for livoletide/AZP–531 asset [5].
Beyond the preview
Go deeper on Alizé Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alizé Pharma.